Oryzon begins Phase I trials on ORY-1001 drug for acute myeloid leukemia
The trial will be carried out at Vall d’Hebrón Hospital in Barcelona with the hematology team led by Francesc Bosch
Oryzon Genomics has announced the beginning of Phase I trials on their drug ORY-1001. This oral drug inhibits the LSD1 enzyme thus limiting the power of leukemic stem cells, reducing colony formation and curbing proliferation. LSD1 (Lysine Specific Demethylase-1) is an epigenetic modulator that regulates gene activity, and this is the first trial launched that targets it.
As there are currently limited therapeutic options for acute myeloid leukemia, the news has been received with heightened expectations. As Chief Scientific Officer Tamara Maes explains, “We are hopeful that ORY-1001 will contribute to treatment of leukemia patients and will continue to explore its potential for other oncological diseases.”
The trial on this new drug will be conducted at Vall d’Hebrón Hospital in Barcelona with the hematology team led by Francesc Bosch. Last June, Oryzon presented their breakthroughs at a congress in the United States, and soon after received orphan drug designation for ORY-1001.
- Related news (17/06/2013)
- Related news (30/07/2013)
More information is available in the Oryzon Genomics press release.